BioInformant

Your Global Leader in Stem Cell Market Research

MENUMENU
  • Blog
    • Interviews
  • News
  • Stem Cells
    • iPS Cells
    • MSCs
    • HSCs
    • Adipose SCs
    • Neural Stem Cells
  • Exosomes
  • CAR-T
  • Cord Blood
  • Shop
    • Products
    • Submit PR
    • Advertise
  • About
    • Testimonials
    • Story
    • Guarantee
    • Contact
  • Home
  • Blog
    • Stem Cells
      • HSCs
      • iPS Cells
      • MSCs
      • Neural Stem Cells
      • Adipose SCs
    • Exosomes
    • Cell Therapy
      • CAR-T
    • Cord Blood
    • Stem Cell News
    • Interviews
  • COVID-19
  • Shop
  • Submit PR
  • Company
    • Advertise
    • Testimonials
    • Story
    • Job Posts
    • Guarantee
    • Privacy Policy
    • Contact
Home » denovoMATRIX releases isoMATRIX: Cell and Gene Therapy’s first high-yield MSC isolation technology
denovoMATRIX isoMATRIX

denovoMATRIX releases isoMATRIX: Cell and Gene Therapy’s first high-yield MSC isolation technology

December 15, 2021 By Cade Hildreth (CEO) Leave a Comment

DRESDEN, Germany, December 15, 2021 / BioInformant / — denovoMATRIX GmbH, an innovator in cell and gene therapy (CGT) manufacturing, announced the launch of a new technology for bringing down costs and increasing access to high-quality mesenchymal stromal cells (MSCs) for stem cell-based therapies. The technology termed isoMATRIX, is designed to isolate MSCs in xeno-/serum-free conditions with high efficiency and stemness enabling rapid cell expansion for radically reduced cost of goods (COGs) for cell therapy manufacturers.

High-quality and low-cost manufacturing is necessary to bring regenerative therapies to patients. Particularly for MSC-based therapies, the low number of cells in the source material and their limited expansion time in addition to the high cost of goods hamper the widespread application of those life-saving treatments.

MSC-based therapies require regular isolation and expansion due to the limited time MSCs can be cultured ex vivo before their therapeutic potential is affected. Furthermore, donor approval, lengthy characterization and the use of good manufacturing practices (GMP) is needed for each lot of isolated MSCs before it can be used in stem cell-based therapies. ‘‘Designed for GMP processes and cell therapies, the isoMATRIX signifies a breakthrough in MSC manufacturing efficiency. The technology significantly increases the number of tissue-isolated MSCs, which raises the cell yield that can be generated from a single donor’’ says Dr. Kristina Thamm, Head of Project Services at denovoMATRIX. ‘‘We see the isoMATRIX as a key opportunity to enable industry players in the MSC therapies space, and would pursue an out-licensing strategy for this technology’’ continues Dr. Dejan Hušman, CEO of denovoMATRIX.

isoMATRIX figure

The key innovations of the isoMATRIX are twofold.

Pluristyx

Using isoMATRIX to isolate MSCs from bone marrow aspirates or adipose tissue results in up to 35% more isolated cells compared to standard isolation procedures.  As shown in the figure, starting the manufacturing process with a higher number of cells results in a strong increase in overall yield, which is the first xeno-/serum-free product to exhibit this behavior. Furthermore, MSCs isolated with the isoMATRIX proliferate on average 33% faster indicating that total manufacturing time can also be reduced. Detailed scientific data supporting these claims can be found here.

denovoMATRIX

About denovoMATRIX GmbH

denovoMATRIX deploys a modular, biomimetic coating technology to enable high performance cell culture, bringing cell therapies to patients and accelerating the path to market for clean meat. The company leverages chemical synthesis, stem cell biology and design thinking to build a platform of biomaterials which address major life science challenges. By providing both cell-based therapy and clean meat companies with solutions, denovoMATRIX is at the forefront of innovation in cell manufacturing processes.

For more information, visit: https://www.denovomatrix.com/isomatrix/

Contact
denovoMATRIX GmbH
Dejan Husman
Tatzberg 47/49
01307 Dresden
mail@denovomatrix.com

5/5 - (1 vote)

Filed Under: MSCs, Press Releases, Stem Cell News

Related

About Cade Hildreth (CEO)

Cade Hildreth is the Founder of BioInformant.com, the world's largest publisher of stem cell industry news. Cade is a media expert on stem cells, recently interviewed by the Wall Street Journal, Los Angeles Business Journal, Xconomy, and Vogue Magazine. 

Tell Us What You Think! Cancel reply

Nanocellect

Marathon Products

Let’s Get Social

  • Facebook
  • Twitter
  • LinkedIn
  • Pinterest
  • Instagram
Menu
  • Blog
  • Stem Cell News
    • Press Releases
  • Stem Cells
    • HSCs
    • iPS Cells
    • MSCs
    • Neural Stem Cells
    • Adipose SCs
  • Exosomes
  • Cell Therapy
    • CAR-T
  • Cord Blood
  • Interviews

Cart

Featured Posts

Cord Blood Market Segmentation

Cord Blood Market Segmentation – Biobanking, HSCT, Cellular Therapy, Genetic Manipulation, & Research Tools

CAR-T Companies

CAR-T Cell Companies Proliferate: List of CAR-T Companies Worldwide

Who discovered stem cells?

Who Discovered Stem Cells? The Answers Revealed

My Tweets

BioInformant's World-Class Clients

  • Submit Press Release
  • Advertise
  • Privacy and Terms

Copyright © 2022 · BIOINFORMANT, Your Global Leader in Stem Cell Market Research

| Email: Info@BioInformant.com | Phone: 703-859-7617 |

800 Corporate Drive, Suite 301, Stafford, VA 22554, United States

Disclaimer: All statements made on this website are NOT expressed as medical claims or advice. They are not intended to diagnose, treat, cure or prevent any disease or condition. If you have a health condition or concern, consult your physician or health care provider.